The control of dopamine neuron development, function and survival: Insights from transgenic mice and the relevance to human disease

被引:33
作者
Eells, JB [1 ]
机构
[1] NIDDKD, NIH, Bethesda, MD 20892 USA
关键词
dopamine neurotransmission; transgenic mice; knockout mice;
D O I
10.2174/0929867033457700
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transgenic technology, especially the use of homologous recombination to disrupt specific genes to produce knockout mice, has added considerably to the understanding of dopamine (DA) neuron develop survival and function. The current review summarizes results from knockout mice with the target disruption of genes involved in the development of DA neurons (engrailed I and 2, 1mx1b, and Nurr1), in 4 maintaining DA neurotransmission (tyrosine hydroxylase, vesicular monoamine transporter, DA transporter, DA D2 and D3 receptors) and important for DA neuron survival (alpha-synuclein, glia cell line-derived neurotrophic factor and superoxide dismutase). As alterations in DA neurotransmission have been implicated in a number of human neuropathologies including Parkinson's disease, schizophrenia and attention deficit/hyperactivity disorder, understanding how specific genes are involved in the function of DA neurons and the compensatory changes that result from loss or reduction in gene expression could provide important insight for the treatment of these diseases.
引用
收藏
页码:857 / 870
页数:14
相关论文
共 163 条
  • [1] Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
    Abeliovich, A
    Schmitz, Y
    Fariñas, I
    Choi-Lundberg, D
    Ho, WH
    Castillo, PE
    Shinsky, N
    Verdugo, JMG
    Armanini, M
    Ryan, A
    Hynes, M
    Phillips, H
    Sulzer, D
    Rosenthal, A
    [J]. NEURON, 2000, 25 (01) : 239 - 252
  • [2] Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
    Abi-Dargham, A
    Rodenhiser, J
    Printz, D
    Zea-Ponce, Y
    Gil, R
    Kegeles, LS
    Weiss, R
    Cooper, TB
    Mann, JJ
    Van Heertum, RL
    Gorman, JM
    Laruelle, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) : 8104 - 8109
  • [3] Parkinson's disease - Redox mechanisms
    Adams, JD
    Chang, ML
    Klaidman, L
    [J]. CURRENT MEDICINAL CHEMISTRY, 2001, 8 (07) : 809 - 814
  • [4] The GDNF family: Signalling, biological functions and therapeutic value
    Airaksinen, MS
    Saarma, M
    [J]. NATURE REVIEWS NEUROSCIENCE, 2002, 3 (05) : 383 - 394
  • [5] Amara S G, 1993, Curr Opin Neurobiol, V3, P337, DOI 10.1016/0959-4388(93)90126-J
  • [6] Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP
    Andreassen, OA
    Ferrante, RJ
    Dedeoglu, A
    Albers, DW
    Klivenyi, P
    Carlson, EJ
    Epstein, CJ
    Beal, MF
    [J]. EXPERIMENTAL NEUROLOGY, 2001, 167 (01) : 189 - 195
  • [7] Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice
    Asanuma, M
    Hirata, H
    Cadet, JL
    [J]. NEUROSCIENCE, 1998, 85 (03) : 907 - 917
  • [8] PARKINSONIAN-LIKE LOCOMOTOR IMPAIRMENT IN MICE LACKING DOPAMINE D2 RECEPTORS
    BAIK, JH
    PICETTI, R
    SAIARDI, A
    THIRIET, G
    DIERICH, A
    DEPAULIS, A
    LEMEUR, M
    BORRELLI, E
    [J]. NATURE, 1995, 377 (6548) : 424 - 428
  • [9] Mitochondrial Dysfunction in Neurodegenerative Diseases
    Johri, Ashu
    Beal, M. Flint
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 342 (03) : 619 - 630
  • [10] Inhibition of dopamine release via presynaptic D2 receptors:: Time course and functional characteristics in vivo
    Benoit-Marand, M
    Borrelli, E
    Gonon, F
    [J]. JOURNAL OF NEUROSCIENCE, 2001, 21 (23) : 9134 - 9141